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Matrix metalloproteinases (MMPs) – zinc containing endopep-
tidases which cleave the different components of the extracellu-
lar matrix. However, not all biological mechanisms and the
effects of these endopeptidases are well-established. Previously
it was believed that MMP functions only as proteolytic enzymes,
but it was found later that MMPs could act as regulators of protein
kinase signal transduction pathways by modifying receptors and
signaling molecules.
One of the most important substrates for MMP is transforming
growth factor-b (TGF-bÞ, which is a receptor for the ligand TGF-b-
signal transduction pathway comprises a network of protein
kinase pathways responsible for many of the processes of tumor
progression, including epithelial mesenchymal transformation
(EMT). Despite the fact that melanoma cells are not of epithelial
origin, they express the epithelial E-cadherin that is necessary
for their interaction with the basal layers of the epidermis. The
degradation of the extracellular matrix and loss of expression of
E-cadherin are major changes needed to start the processes of
melanoma invasion. One of the markers of EMT is a transcription
factor twist1. Twist1 activates the processes of epithelial-
mesenchymal transformation and increases the invasion of mel-
anoma cells by increasing transcription of MMP. The aim of this
study was to evaluate expression levels TGF-b, twist1 under selec-
tive inhibition of MMP-9 and combined inhibition of MMP-9 and-
13 in melanoma model in vivo; to determine the role of MMPs as
possible regulators of TGF-b-way signal transduction, as well as
associated with TGF-b EMT process.
The study was approved by the local Ethic Committee (proto-
col No. 144/ 2012 of 15.11.2012). Melanoma B16-bearing mice (con-
trol group consisted of 7 animals, MMP-9 inhibitor treatment
group – 7, MMP-9/13 inhibitor treatment group – 7 animals) under-
went experimental treatment by MMP inhibitor (Calbiochem,
USA) by daily application within 7 days. Control group consisted
of animals without treatment. Efficacy of MMP-9 inhibition was
evaluated by gelatinize zymography. TGF-b1 and twist 1 tran-
scription factor expression was determined by PCR real-time
using StepOne System (Applied Biosystems, USA). Statistical
analysis was done by Kruskal–Wallis test and Multiple Compar-
isons. The P values lower 0.05 were considered as significant.
It was found that the selective inhibition of MMP-9 did not
induce changes in expression levels of TGF-b and twist1, however,
the combined inhibition of MMP-9 and MMP-13 significantly
reduced the expression levels of the transcription factor twist1
and TGF-b. The results show that MMP-9 and MMP-13 act as acti-
vators of TGF-b-signal transduction pathway and could be consid-
ered as potential molecular targets for experimental therapy for
cancer.
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In 2004, COP1 was characterized as p53 E3-specific human
ubiquitin ligase according to in vitro studies. Later, oncogenic
activity of COP1 and correlation of its overexpression with level
of p53 protein in clinical tumor samples and cell lines were
shown. High expression level of COP1 was described in 25 of 32
cases of breast carcinomas and in 76 out of 171 cases of ovarian
carcinomas. High expression level of COP1 was described in hep-
atocellular carcinoma cell lines (PLC, Hep3B and HepG2, Huh7). In
40 of 55 cases of pancreatic cancer, overexpression of COP1 was
also noted. Some types of leukemia, melanoma, breast, lung
and prostate cancer contain focal deletions of COP1. COP1 overex-
pression was also found in non- oncological diseases like
Duchenne muscular dystrophy, ischemic cardiomyopathy and
juvenile dermatomyositis.
Similar to other p53-related E3 -ubiquitin ligases COP1 has dif-
ferent substrates. The selection of target for ubiquitination
depends on cell type or differentiation stage. Among the sub-
strates of COP1, besides p53 are: c-Jun, ETV1, ACC, TORC2, FOXO1
and C/EBPa, FIP200.
To identify novel proteins that interact with COP1 we applied
proteomics. Proteins co-immunoprecipitated with COP1 were
analyzed by MALDI -TOF mass spectrometry. To achieve this,
COP1–3xFlag expression vector was generated and transfected
into HEK 293T cells by calcium phosphate transfection method.
Protein complexes were immunoprecipitated with anti-FLAG
beads. Bound proteins were then separated by 1D SDS–PAGE gel
electrophoresis and analyzed by means of ESI-LC/MS/MS mass
spectrometry. Subsequent bioinformatics analysis of the interact-
ing proteins was employed. About 25% of identified proteins were
attributed to the cytoskeleton proteins, almost 20% of proteins
had known role in metabolism. According to the literature data,
it was not surprising to find several proteins involved in the lipid
metabolism. Finally, a significant groups of interactants play role
in transcription, cell adhesion, apoptosis, protein modification
and transport. It is important to note that several COP1-bound
proteins can be strong regulators of cell cycle in G2/M transition.
Our data can be used for the subsequent studies of previously
unknown roles of COP1 in different diseases.
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